Cytokine Signalling Forum

Publications





August 19

Effet du Filgotinib par rapport au placebo sur la réponse clinique chez des patients atteints de Polyarthrite Rhumatoïde modérée à sévère réfractaire au traitement antirhumatismal modificateur de la maladie: l'essai clinique randomisé FINCH 2

Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, �Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T.
JAMA 2019 322(4):315-325

Among RA patients with an inadequate response or intolerance to bDMARDs, filgotinib (FIL) doses, compared to PBO resulted in significantly greater proportions achieving a clinical response at Wk12. Patients with active RA despite treatment with bDMARD therapy need treatment options. The FINCH 2 Phase 3 study compared the effects of FIL vs PBO for the treatment of RA patients with inadequate response or intolerance to ≥1 prior bDMARDs. Patients were randomized in a 1:1:1 ratio, receiving FI...

Mots clefs: JAK, Filgotinib, Clinical, Efficacy

Traduit par: Farese